• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Tandem Diabetes Care touts study results for insulin pump with closed-loop technology

June 4, 2021 By Sean Whooley

Tandem Diabetes Care tslim_X2_Insulin_Pump_Front_View_Control-IQ_RGB
Image from Tandem Diabetes

Tandem Diabetes Care (NSDQ:TNDM) today shared real-world data on its t:slim X2 insulin pump with Control-IQ advanced hybrid closed-loop technology.

Presenting at the 14th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD), the company touted immediate and sustained improvements in time-in-range (TIR) observed in more than 9,000 people with diabetes using the system for 12 months.

San Diego-based Tandem reported glycemic trends in type 1 diabetes patients based on their time of adoption of the t:slim X2 insulin pump with Control-IQ technology. A study sample included 6,233 people with type 1 diabetes who initiated use of the technology between its launch on Jan. 15, 2020, and July 15, 2020. That population was divided into three groups — those who adopted within four weeks of launch (Group A), between three and four months (B) and five and six months (C).

Regardless of which group participants fell into, Tandem reported that all groups experienced significant improvements in sensor TIR, according to a news release.

The company also reported on a study sample of diverse groups of people with type 1 diabetes with 700 participants who uploaded at least 21 days of pump data to Tandem’s web application and had at least 75% CGM use during this period. Among that group, TIR measured a 72.5% median, while quality of life survey measures showed significant reductions in diabetes impact and greater satisfaction with Control-IQ technology compared to previous insulin delivery devices.

A presentation of outcomes from 12 consecutive months of real-world Control-IQ use reported a median TIR of 73.6%, marking an increase of 10% from the baseline measurement. The median percent time in automation or “closed-loop” came in at 94.2%, while the median percent time below 70 mg/dL hit approximately 1%.

Tandem also reported on real-world analysis of more than 72,000 individuals using Control-IQ, with a significant improvement demonstrated in nighttime glycemic control. Patient-reported outcomes also confirmed a decrease in diabetes burden and an increase in device satisfaction.

“Experience matters in automated insulin dosing systems, and Control-IQ technology is performing as well in the real world as it did in the pivotal studies,” Tandem Diabetes Care medical director Dr. Jordan Pinsker said in the news release. “Additionally, patient-reported outcomes, including reduced diabetes burden and improved sleep quality, demonstrate that our Control-IQ technology can make a positive and sustained impact on the lives of people with diabetes.”

Filed Under: Auto-injectors, Big Data, Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring Tagged With: Tandem Diabetes Care

IN CASE YOU MISSED IT

  • Medtronic to separate Diabetes business unit
  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS